Preferred Label : tremelimumab;

MeSH note : a fully human anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for immunotherapy of metastatic melanoma.;

MeSH hyponym : CP675 cpd; CP-675; CP-675206; CP675206; CP 675206;

Is substance : O;

UNII : QEN1X95CIX;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3418058/fr/imjudo-tremelimumab-carcinome-hepato-cellulaire
2023
false
false
false
France
insurance, health, reimbursement
treatment outcome
tremelimumab
antineoplastic agents
antineoplastic combined chemotherapy protocols
durvalumab
adult
Advanced Hepatocellular Carcinoma
Unresectable Hepatocellular Carcinoma
Child-Pugh Class A
ECOG Performance Status 0
ECOG Performance Status 1
Durvalumab/Tremelimumab Regimen
evaluation of the transparency committee
carcinoma, hepatocellular
tremelimumab

---
Imjudo - tremelimumab
https://www.ema.europa.eu/en/medicines/human/EPAR/imjudo
2023
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
tremelimumab
tremelimumab
orphan drug production
drug approval
europe
tremelimumab
antineoplastic agents
antineoplastic agents
carcinoma, hepatocellular
Unresectable Hepatocellular Carcinoma
Advanced Hepatocellular Carcinoma
antineoplastic combined chemotherapy protocols
durvalumab
Durvalumab/Tremelimumab Regimen
infusions, intravenous
CTLA4 protein, human
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
Female of Childbearing Potential
drug evaluation, preclinical

---
https://www.has-sante.fr/jcms/p_3459834/fr/imfinzi-/-tremelimumab-astrazeneca-durvalumab-/-tremelimumab-cancer-bronchique-non-a-petites-cellules-cbnpc
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
platinum compounds
antineoplastic combined chemotherapy protocols
Antineoplastic Agents, Immunological
bronchial neoplasms
neoplasm metastasis
Metastatic Lung Non-Small Cell Carcinoma
Activating EGFR Gene Mutation Negative
Activating ALK Gene Mutation Negative
Durvalumab/Tremelimumab Regimen
evaluation of the transparency committee
tremelimumab
carcinoma, non-small-cell lung
durvalumab

---
https://ansm.sante.fr/tableau-acces-derogatoire/tremelimumab
2023
false
false
false
France
French
drug information
tremelimumab
carcinoma, hepatocellular

---
https://www.has-sante.fr/jcms/p_3448228/fr/imjudo-/-imfinzi-tremelimumab-/-durvalumab-carcinome-hepato-cellulaire-chc
2023
false
false
false
France
antineoplastic combined chemotherapy protocols
Durvalumab/Tremelimumab Regimen
insurance, health, reimbursement
treatment outcome
infusions, intravenous
adult
Advanced Adult Hepatocellular Carcinoma
Unresectable Hepatocellular Carcinoma
Child-Pugh Class A
ECOG Performance Status 0
ECOG Performance Status 1
evaluation of the transparency committee
carcinoma, hepatocellular
durvalumab
tremelimumab

---
Tremelimumab AstraZeneca - tremelimumab
https://www.ema.europa.eu/en/medicines/human/EPAR/tremelimumab-astrazeneca
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
tremelimumab
tremelimumab
tremelimumab
antineoplastic agents
antineoplastic agents
carcinoma, non-small-cell lung
neoplasm metastasis
adult
antineoplastic combined chemotherapy protocols
Metastatic Lung Non-Small Cell Carcinoma
durvalumab
carboplatin
cisplatin
infusions, intravenous
CTLA4 protein, human
product surveillance, postmarketing
Activating EGFR Gene Mutation Negative
Activating ALK Gene Mutation Negative
drug interactions
pregnancy
breast feeding
Female of Childbearing Potential
drug evaluation, preclinical

---
Nous contacter.
19/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.